StockData
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. (ACRV) stock

ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $61.28MP/E –Yield –

Acrivon Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Acrivon Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $57.40M, down 16.9% year over year. For fiscal 2025 it was $59.99M, down 6.3% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$59.99M-6.3%
FY2024Dec 31, 2024$63.99M+39.0%
FY2023Dec 31, 2023$46.02M+92.2%
FY2022Dec 31, 2022$23.95M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$13.84M-14.4%
Q1 FY2026Mar 31, 2026$15.17M-1.6%
Q4 FY2025Dec 31, 2025$14.75M-20.8%
Q3 FY2025Sep 30, 2025$13.65M-27.7%
Q2 FY2025Jun 30, 2025$16.18M+7.7%
Q1 FY2025Mar 31, 2025$15.41M+34.4%
Q4 FY2024Dec 31, 2024$18.63M+20.4%
Q3 FY2024Sep 30, 2024$18.86M+83.7%
Q2 FY2024Jun 30, 2024$15.03M+42.8%
Q1 FY2024Mar 31, 2024$11.47M+17.6%
Q4 FY2023Dec 31, 2023$15.48M–
Q3 FY2023Sep 30, 2023$10.27M–
Q2 FY2023Jun 30, 2023$10.52M–
Q1 FY2023Mar 31, 2023$9.76M–

More Acrivon Therapeutics figures

See a number that looks wrong?